HORIZON EUROPE
European
Specific Challenge:The world is facing a critical healthcare problem: due to a growing and aging population increasingly exposed to a number of well-known and new risk factors, cancer is becoming one of the most important public health problems worldwide.
In 2012, the incidence of new cancer cases in the Community of Latin American and Caribbean States (CELAC) countries was 1.1 million, with 0.6 million deaths; in Europe the incidence was 3.45 million new cases, with 1.75 million deaths[1]. Moreover, about two-thirds of all cancer deaths occur in low- and middle-income countries and incidence and mortality are expected to increase by about 75% in these countries by 2030[1].
Current cancer care does not fully reflect ethnic, cultural, environmental and resource differences. In addition, limited research is being conducted on tumours primarily found in CELAC countries.
There is a need to establish evidence obtained through international high-quality translational collaborative research to tailor cancer control to specific patient groups.
Scope:Proposals must focus on translational and multidisciplinary research to identify...
see more
Specific Challenge:The world is facing a critical healthcare problem: due to a growing and aging population increasingly exposed to a number of well-known and new risk factors, cancer is becoming one of the most important public health problems worldwide.
In 2012, the incidence of new cancer cases in the Community of Latin American and Caribbean States (CELAC) countries was 1.1 million, with 0.6 million deaths; in Europe the incidence was 3.45 million new cases, with 1.75 million deaths[1]. Moreover, about two-thirds of all cancer deaths occur in low- and middle-income countries and incidence and mortality are expected to increase by about 75% in these countries by 2030[1].
Current cancer care does not fully reflect ethnic, cultural, environmental and resource differences. In addition, limited research is being conducted on tumours primarily found in CELAC countries.
There is a need to establish evidence obtained through international high-quality translational collaborative research to tailor cancer control to specific patient groups.
Scope:Proposals must focus on translational and multidisciplinary research to identify specific patient groups in view of improving one or more of the following aspects: screening, early detection, diagnosis, and/or prognosis.
Proposals must build on the diverse genetic backgrounds, risk factors, cancer incidence[3], geographical environment, and/or different healthcare models (including social care and volunteers) in European and CELAC countries.
Proposals may integrate molecular, behavioural, nutritional, clinical, social and environmental epidemiology[4] data from cohorts; registries; biobanks; repositories; research infrastructures;
Considerations of effectiveness and potential clinical benefit should be integrated in the proposals where relevant.
Specific population age groups, sex and gender aspects, socio-economic, ethical, ethnic, cultural, lifestyle and behavioural factors and any other non-health related individual attributes should be taken into consideration where relevant.
Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least two participants from two different CELAC countries[5].
The Commission considers that proposals requesting a contribution from the EU of between EUR 2 to 4 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.
Expected Impact:The proposals should address one of or combinations of:
Identify high-risk populations with a view to tailor early detection and diagnosis or to optimise prevention. Improve early detection and/or diagnosis and/or prognosis of cancer adapted to specific settings. Provide evidence to national programmes and policies focusing on screening, early detection and/or diagnosis and/or prognosis. Provide novel opportunities for the development of targeted therapies. Contribute to attaining sustainable development goals for non-communicable diseases[6]
Cross-cutting Priorities:Socio-economic science and humanitiesInternational cooperationGenderOpen Science
[1]http://www.iarc.fr
[2]http://www.iarc.fr
[3]For instance, cancers proportionally more frequent in the CELAC region include gastric, cervical, gallbladder, childhood leukaemia
[4]including environmental carcinogens, e.g. in homes, occupational, urban and rural settings
[5]CELAC countries: Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Grenada, Guyana, Jamaica, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Lucia, Saint Kitts and Nevis, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela.
[6]https://sustainabledevelopment.un.org/sdg3
see less
Consortium characteristics
:
The aid is European, you can apply to this line any company that is part of the European Community.
characteristics of the Proyecto
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Characteristics of financing
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least two participants from two different CELAC countries.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion in a single stage process will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Acti... 1. Eligible countries: described in Annex A of the Work Programme.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon 2020 projects. See the information in the Online Manual.
2. Eligibility and admissibility conditions: described in Annex B and Annex C of the Work Programme.
Due to the specific challenge of this topic, in addition to the minimum number of participants set out in the General Annexes, proposals shall include at least two participants from two different CELAC countries.
Proposal page limits and layout: please refer to Part B of the proposal template in the submission system below.
3. Evaluation:
Evaluation criteria, scoring and thresholds are described in Annex H of the Work Programme.
Submission and evaluation processes are described in the Online Manual.
The thresholds for each criterion in a single stage process will be 4 (Excellence), 4 (Impact) and 3 (Implementation). The cumulative threshold will be 12.
4. Indicative time for evaluation and grant agreements:
Information on the outcome of evaluation (single-stage call): maximum 5 months from the deadline for submission.
Signature of grant agreements: maximum 8 months from the deadline for submission.
5. Proposal templates, evaluation forms and model grant agreements (MGA):
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template
Standard evaluation form
General MGA - Multi-Beneficiary
Annotated Grant Agreement
Essential information for clinical studies
6. Additional provisions:
Horizon 2020 budget flexibility
Classified information
Technology readiness levels (TRL) – where a topic description refers to TRL, these definitions apply.
Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.
8. Additional documents:
Introduction WP 2018-20
Health, demographic change and well-being WP 2018-20
General annexes to the Work Programme 2018-2020
Legal basis: Horizon 2020 Regulation of Establishment
Legal basis: Horizon 2020 Rules for Participation
Legal basis: Horizon 2020 Specific Programme
7. Open access must be granted to all scientific publications resulting from Horizon 2020 actions.
Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
Open access to research data
The Open Research Data Pilot has been extended to cover all Horizon 2020 topics for which the submission is opened on 26 July 2016 or later. Projects funded under this topic will therefore by default provide open access to the research data they generate, except if they decide to opt-out under the conditions described in Annex L of the Work Programme. Projects can opt-out at any stage, that is both before and after the grant signature.
Note that the evaluation phase proposals will not be evaluated more favourably because they plan to open or share their data, and will not be penalised for opting out.
Open research data sharing applies to the data needed to validate the results presented in scientific publications. Additionally, projects can choose to make other data available open access and need to describe their approach in a Data Management Plan.
Projects need to create a Data Management Plan (DMP), except if they opt-out of making their research data open access. A first version of the DMP must be provided as an early deliverable within six months of the project and should be updated during the project as appropriate. The Commission already provides guidance documents, including a template for DMPs. See the Online Manual.
Eligibility of costs: costs related to data management and data sharing are eligible for reimbursement during the project duration.
The legal requirements for projects participating in this pilot are in the article 29.3 of the Model Grant Agreement.
Additional information about the call
other advantages
